Iza-bren shows 59% reduction in disease progression in breast cancer

Bristol Myers Squibb reported that its drug izalontamab brengitecan reduced the risk of progression or death by 59% compared to chemotherapy in HR+/HER2- breast cancer, with a median progression-free survival of 8.2 months versus 4.0 months. The company noted that overall survival data is not yet mature.

Bristol Myers Squibb's breast cancer drug, iza-bren, delayed disease progression for a median 8.2 months in a Phase 3 trial, versus 4 months with chemotherapy. The drug reduced the risk of progression or death, with manageable safety profile. Results will be presented at ESMO 2026. Iza-bren has shown clinical benefit in five tumor types, including breast and lung cancer, and has Breakthrough Therapy Designation. The drug is being developed under a license agreement with SystImmune.

Bristol-Myers Squibb (BMY) reported positive trial data for RYZ101 and progress in multiple myeloma, potentially broadening revenue sources. Q2 revenue grew 6% to $12.97B, with the Growth Portfolio up 15%. The company raised 2026 guidance to $49B-$50B in revenue and $6.75-$7.00 in non-GAAP EPS, but faces patent and generic pressure on older drugs.

HSBC reduced its price target for Bristol-Myers Squibb from $65 to $60. The stock is currently trading at $59.75, with a 5-day change of -1.35% and a year-to-date change of +10.77%.

Bristol Myers Squibb's experimental pulmonary fibrosis drug admilparant met the main goal at 60 mg in a phase 3 trial but missed the target at 120 mg. The company reported topline results, with detailed data to be presented later. Both doses were well tolerated, but one death occurred in the 120 mg group. BMS shares fell about 3% in early trading.

Bristol Myers Squibb reported positive topline results from a Phase 3 trial for its investigational IPF treatment, highlighting progress in addressing the disease.